Medical knowledge.
Clearly explained.

Quick comparison

Correction to the reference image: crackles are not always caused by fluid or mucus, and rhonchi are not simply “expiratory wheezing”.

Clinical examination notes

1. Assess severity first: use ABCDE if unwell. Record respiratory rate, SpO₂, pulse, BP, temperature and consciousness; assess speech and work of breathing.
2. Listen systematically: compare corresponding areas of both lungs, including posterior bases, directly on skin. Ask for slightly deeper breaths through the mouth and pause if dizzy.
3. Describe the finding: timing, pitch, site, symmetry, air entry and change after coughing. Add percussion, chest expansion and relevant cardiac findings.
4. Investigate the suspected cause: tests may include chest imaging, peak flow when feasible, blood gas in severe illness, or later spirometry. Do not delay emergency treatment to complete tests.

Other useful findings: bronchial breathing over peripheral lung suggests consolidation; reduced or absent sounds may reflect pleural fluid, pneumothorax or obstruction. A pleural rub is a grating sound associated with inflamed pleural surfaces.

Public notes: when to seek help

Noisy breathing does not tell you the cause on its own. Arrange medical review for new or persistent wheezing, recurrent chest symptoms or worsening breathlessness.

In the UK, call 999 for severe breathing difficulty, inability to get words out, a tight or heavy chest, very pale/blue/grey lips or skin, or sudden confusion. Noisy breathing with throat or tongue swelling is also an emergency. Do not drive yourself.

For breathlessness worse than usual without emergency signs, contact NHS 111. Follow your prescribed asthma action plan if you have one, and seek emergency help if symptoms are severe or worsening.

What this means in practice

Continue current UK and local pathways. This week produced no sufficiently robust, newly published evidence that should change antibiotic timing or haemodynamic resuscitation in sepsis; ACS rule-out or antithrombotic practice; acute stroke reperfusion selection; IM adrenaline treatment for anaphylaxis; severe-asthma escalation; PE reperfusion or disposition; DKA fluid and insulin management; or emergency potassium-lowering treatment.

1. ICare-FASTER: point-of-care hs-cTnI shortened ED stay

In a pragmatic stepped-wedge cluster-randomised trial across six New Zealand EDs, 59,980 presentations were managed with the same accelerated diagnostic pathway using either central-lab high-sensitivity troponin or whole-blood point-of-care hs-cTnI. Point-of-care testing reduced adjusted ED length of stay by 13% —47 minutes from a control mean of 376 minutes. MI or cardiac death at 30 days was 0.39% in both groups.

Practical implication: for UK departments with slow laboratory turnaround, validated point-of-care high-sensitivity assays may be a credible operational strategy to reduce occupancy. This is an assay-and-pathway implementation result, not permission to improvise thresholds or diagnose ACS from troponin alone.

Caveats: the trial was conducted in New Zealand, used a stepped-wedge service implementation design and studied one point-of-care assay within a defined pathway. UK adoption requires local analytical governance, assay-specific cut-offs, quality control, training and cost-effectiveness assessment.

2. MILD-MT: thrombectomy benefited imaging-selected mild LVO stroke

This open-label multicentre Chinese trial randomised 304 people with anterior-circulation large-vessel occlusion, NIHSS below 6, a small infarct core and substantial perfusion mismatch within 24 hours. At 90 days, modified Rankin score 0–1 occurred in 69.4% with endovascular therapy plus medical care versus 50.0% with medical care alone (odds ratio 2.32, 95% CI 1.41–3.81). Symptomatic intracranial haemorrhage occurred in three patients in each group, but serious procedure-related complications occurred in 13.2% of the intervention group.

Practical implication: mild symptoms should not prevent urgent vascular imaging or thrombectomy-centre discussion when an LVO is suspected, especially with a disabling deficit. The result supports specialist selection, not automatic thrombectomy for every NIHSS 0–5 stroke.

Caveats: this was a relatively small, open-label trial from China in a highly selected perfusion-mismatch population. Procedure-related harm was appreciable, and UK pathways should not change before guideline and stroke-network review or corroborating trials.

What is new?

A prespecified secondary analysis of the prospective PRESTO study enrolled 642 adults with suspected acute myocardial infarction across four NHS ambulance services; 80 (12.5%) had adjudicated type 1 MI. A newly derived 0/1-hour point-of-care hs-cTnI pathway—an arrival value below 5 ng/L, or a 1-hour value below 10 ng/L with an absolute change below 1 ng/L—classified 328 patients (51.1%) as rule-out. Sensitivity was 98.8% and negative predictive value 99.7%.

T-MACS applied to the same serial measurements ruled out fewer patients (28.0%) with the same 98.8% sensitivity; it produced the strongest rule-in positive predictive value at 95.4%.

Practical clinical implication

This provides a credible UK pathway for future prospective ambulance validation and may ultimately reduce unnecessary ED conveyance. For current practice, it supports service-level research and pathway design—not individual clinician deviation from existing chest-pain pathways. Continue ECG-led assessment, appropriate hospital conveyance and validated local troponin algorithms; a reassuring prehospital result must not override ongoing ischaemic symptoms, dynamic ECG changes, instability or an alternative serious diagnosis.

1. Early metformin in GDM: a stronger glycaemic signal, but no new UK indication

Type: Post-hoc secondary analysis of the double-masked EMERGE randomised trial, published 3 November; 526 pregnancies with GDM diagnosed using WHO 2013 criteria.

What is new: A generalized pairwise comparison, which ranked insulin initiation ahead of fasting hyperglycaemia, favoured immediate metformin over placebo: win ratio 1.46 (95% CI 1.13–1.89) and net treatment benefit 13.7 percentage points. The largest separation was for starting insulin (win ratio 1.68).

How this differs: The original conventional analysis did not show superiority for its composite primary outcome (56.8% vs 63.7%; RR 0.89, 95% CI 0.78–1.02), although insulin use was lower with metformin. The new result changes the statistical framing, not the underlying participants or events. NICE currently recommends diet and exercise first when fasting glucose is below 7 mmol/L, then metformin if targets remain unmet after 1–2 weeks.

Why it matters: Avoiding insulin can reduce treatment burden, but the reanalysis does not establish that immediate metformin improves maternal or neonatal morbidity.

Practice take-home: Continue NICE NG3. Do not make universal day-of-diagnosis metformin routine on this secondary analysis alone. It can support shared discussion when medication is needed, while accounting for glucose profile, preferences and gastrointestinal adverse effects.

Uncertainty: The hierarchy, weights and estimands were chosen after trial completion, so the authors describe the result as exploratory. This was a two-centre Irish trial, 80% of participants were White European, and the diagnostic and treatment thresholds differ from NICE practice.

2. Sacituzumab tirumotecan improved both PFS and survival in pretreated endometrial cancer

Type: TroFuse-005 international, open-label phase 3 randomised trial; published online 26 October and included as a late-indexed practice-changing gynaecological-oncology study missed by the previous brief.

What is new: In 776 patients with advanced or recurrent endometrial carcinoma or carcinosarcoma previously treated with platinum chemotherapy and PD-1/PD-L1 therapy, sacituzumab tirumotecan improved median progression-free survival from 3.9 to 7.2 months (HR 0.59, 95% CI 0.50–0.70) and median overall survival from 12.1 to 19.0 months (HR 0.68, 95% CI 0.55–0.84) versus physician's choice of doxorubicin or paclitaxel.

How this differs: Later-line treatment after both platinum and immunotherapy has had limited effective options. This is the first phase 3 evidence supporting this TROP2-directed antibody–drug conjugate in that setting.

Why it matters: The 6.9-month median overall-survival difference is clinically substantial in a poor-prognosis population. Grade 3 or worse adverse events were also more frequent with sacituzumab tirumotecan (69% vs 57%).

Practice take-home: Discuss the result in the gynaecological-oncology MDT and identify trial or access pathways when appropriate, but do not substitute it for current NHS-funded therapy until regulatory approval and NICE commissioning guidance are in place. NICE lists the appraisal as awaiting development.

Uncertainty: The trial was industry funded and open-label, although central radiology review was masked. Longer follow-up, quality-of-life data and UK cost effectiveness remain important.

1. Adding an LNG-IUS at endometrial ablation reduced later hysterectomy

Type: MIRA2 multicentre, open-label randomised superiority trial, published online in The Lancet on 21 October and included here as a late-breaking trial not covered in the previous brief.

What is new: Among 715 women undergoing endometrial ablation for heavy menstrual bleeding, immediate insertion of a 52 mg LNG-IUS reduced hysterectomy within 2 years from 10% (34/331) to 4% (15/342): RR 0.43 (95% CI 0.24–0.77), absolute risk difference 6 percentage points and an approximate number needed to treat of 17. Serious adverse events occurred in 8% of each group.

How this differs: NICE NG88 currently presents the LNG-IUS as first-line medical treatment and second-generation ablation as a later surgical option; it does not recommend their routine combination. The trial supports the combined procedure as a uterus-preserving strategy for women already choosing ablation.

Why it matters: Avoiding around six hysterectomies per 100 treated women is clinically meaningful and could reduce repeat surgery, recovery burden and service use.

Practice take-home: When counselling a suitable patient who has completed childbearing and is proceeding to ablation, discuss concurrent 52 mg LNG-IUS insertion as an evidence-supported option. Explain device-related bleeding or tolerability issues, the need to avoid future pregnancy after ablation, and the absence of UK guideline endorsement so far. Adoption should follow local medicines and procedural governance.

Uncertainty: The study was open-label, conducted in the Netherlands and reports 2-year outcomes. Longer follow-up, UK implementation data and device-removal outcomes remain relevant.

2. Reproductive history should follow the patient into cardiovascular care

Type: Joint AHA, AAP, ACOG and SMFM presidential advisory and consensus scientific statement, published 26 October.

What is new: The societies propose a female-specific life-course framework spanning perimenarche, ovarian cycling, perimenopause and postmenopause. They recommend routinely asking about and documenting hypertensive disorders of pregnancy, gestational diabetes, preterm birth and a small-for-gestational-age infant as later cardiovascular risk enhancers. They also call for cardiovascular–kidney–metabolic assessment and accountable transition from obstetric to longitudinal care after an adverse pregnancy outcome.

How this differs: Reproductive events are often recorded as completed obstetric history rather than retained as active long-term risk information. The framework treats pregnancy as a cardiovascular stress test and links menstrual, hormonal, psychosocial and cardiovascular assessment throughout life.

Why it matters: Risk identified during pregnancy is frequently lost at discharge or the 6-week postnatal review, delaying prevention in women who develop hypertension, diabetes or cardiovascular disease at younger ages.

Practice take-home: Put adverse pregnancy outcomes in the active problem list and discharge summary; arrange a named handover to primary care; ensure indicated BP, lipid, glycaemic and renal assessment; and record premature or early menopause when assessing cardiovascular risk. Use current NICE thresholds and UK risk tools for treatment decisions—the US statement does not replace them.

Uncertainty: This is consensus guidance built from existing evidence rather than a trial of the proposed workflow. The best UK implementation model and the incremental value beyond established risk tools require evaluation.

1. Menopause care should assess sleep and mood—not only vasomotor symptoms

Type: ACOG Clinical Practice Guideline No. 13, published online 15 October and replacing its 2014 practice bulletin. It is included as a late-breaking update not captured in last week's brief.

What is new: Menopausal hormone therapy remains the most effective treatment for bothersome vasomotor symptoms, but ACOG now explicitly addresses menopause-related sleep and mood symptoms. It conditionally supports cognitive behavioural therapy, clinical hypnosis, mindfulness-based interventions, exercise and acupuncture for selected symptoms, and incorporates neurokinin-receptor antagonists among non-hormonal options. Conjugated oestrogen with bazedoxifene is suggested as an alternative to oestrogen–progestogen therapy for suitable patients.

Why it matters: This extends the recent ACP vasomotor-symptom guidance by treating insomnia, anxiety and mood symptoms as problems requiring their own assessment rather than assuming they will resolve when hot flushes improve.

UK take-home: Ask directly about sleep and mood, assess other causes such as depression, anxiety and sleep apnoea, and consider menopause-specific CBT. Continue to follow NICE NG23, UK licensing, formulary restrictions and medicine-specific monitoring; the US guideline does not supersede these. Evidence for most non-pharmacological interventions is weaker than for hormone therapy.

2. Pregnancy after living kidney donation: modestly higher hypertensive and fetal-growth risk

Type: Canadian matched cohort study, published in JAMA on 22 October; 385 donor pregnancies were compared with 1,540 pregnancies in healthy matched nondonors.

What is new: Gestational hypertension, pre-eclampsia or eclampsia occurred in 11.9% of donor pregnancies versus 8.3% of controls (RR 1.51, 95% CI 1.10–2.08). Small-for-gestational-age birth occurred in 13.8% versus 7.9% (RR 1.86, 95% CI 1.37–2.52). Severe maternal morbidity, caesarean birth, postpartum haemorrhage, gestational diabetes, preterm/low-birthweight composite and neonatal intensive-care admission were not significantly increased.

Why it matters: The study is substantially larger than earlier donor-pregnancy cohorts and provides more useful absolute risks for counselling. Most pregnancies after donation remained uncomplicated, so the findings should not be framed as a contraindication to pregnancy.

Practice take-home: Before donation, discuss the modest increase in hypertensive and fetal-growth risk with candidates who may later become pregnant. For a pregnant previous donor, document baseline blood pressure, renal function and proteinuria; involve obstetric medicine, renal or transplant teams as indicated; and maintain careful blood-pressure, proteinuria and fetal-growth surveillance. Do not prescribe aspirin solely because of this observational study—apply current NICE risk assessment.

Uncertainty: Administrative coding, residual confounding, repeated pregnancies and limited power for rare outcomes preclude causal conclusions.

What is new?

The multicentre, cluster-randomised DIFOCCULT-3 substudy included 4,398 adults whose admission ECG did not show diagnostic ST elevation. Compared with conventional STEMI/NSTEMI triage, the occlusive/non-occlusive MI approach selected more patients for invasive management within 2 hours (45.4% versus 13.6%) and identified adjudicated acute coronary occlusion within 2 hours more often (35.1% versus 16.7%), without reducing angiographic yield.

The intervention was not a single ECG rule. It combined clinical assessment, subtle or dynamic ECG findings, AI-supported ECG interpretation and adjunctive testing such as bedside echocardiography to look actively for an occluded culprit artery.

Practical clinical implication

Do not treat “no STEMI criteria” as reassurance when the story still suggests ongoing coronary occlusion. In persistent or recurrent ischaemic pain, haemodynamic or electrical instability, or suspicious dynamic ECG change, repeat the ECG, compare with prior tracings, consider posterior or right-sided leads where appropriate, and seek early senior and cardiology review. Bedside echocardiography may strengthen concern for regional wall-motion abnormality when available, but should not delay reperfusion in a patient who already meets an emergency pathway.

What changed?

Nothing sufficiently robust and clinically consequential to justify a new diagnostic, treatment, counselling or service-delivery recommendation this week. Publications screened in the interval were either preliminary, lower-impact, outside the date window, or did not alter decisions beyond established guidance.

Why this matters

A quiet evidence week should not create artificial practice change. Maintaining stable pathways is safer than adopting weak signals before replication, guideline appraisal or medicines-governance review.

Practical take-home

Continue current NICE, RCOG and local pathways. There is no evidence-based reason from this week's publications to amend protocols, patient information, prescribing or escalation thresholds. Revisit any emerging signal only when a full primary report or authoritative recommendation becomes available.

What is new?

An analysis of 578,204 adult DKA hospitalisations in the US National Inpatient Sample found coded delirium in 1.1%. Patients with delirium had longer median admission (8 versus 3 days) and higher in-hospital mortality (6.4% versus 3.2%). Delirium was also associated with older age, multimorbidity and complications such as sepsis, stroke, pulmonary embolism, acute myocardial infarction and acute kidney injury.

Practical clinical implication

New confusion in an adult with DKA should be treated as a warning sign, not automatically attributed to acidosis. Reassess ABCDE, glucose and osmolality; review fluid, sodium and potassium trends; and actively consider infection, hypoxia, AKI, stroke, substance withdrawal, medication effects and—where clinically plausible— cerebral oedema. Escalate monitoring and senior review when mental status is abnormal or deteriorating.

1. Menopausal vasomotor symptoms: hormone therapy remains first line

Type: American College of Physicians clinical guideline with a supporting systematic review and meta-analysis of 90 randomised trials, published 6 October.

ACP strongly recommends oestrogen plus a progestogen for people with a uterus, or oestrogen alone after hysterectomy, when pharmacological treatment is sought for hot flushes or night sweats and there is no contraindication. If hormone therapy is unsuitable or not tolerated, ACP places venlafaxine or desvenlafaxine second line, followed by escitalopram, paroxetine, gabapentin or a neurokinin-receptor antagonist such as fezolinetant or elinzanetant.

Why it matters: The review found that oestrogen reduced both symptom frequency and severity and improved quality of life. Non-hormonal agents generally reduced frequency, but evidence for reducing severity was weaker. Hormone therapy was judged high economic value; fezolinetant low value in the US analysis.

UK take-home: This broadly reinforces NICE rather than changing UK practice: offer individualised HRT for vasomotor symptoms after assessing contraindications and discussing benefits and risks. NICE permits fezolinetant for moderate-to-severe symptoms when HRT is unsuitable, but the ACP sequence should not override NICE commissioning or product monitoring requirements. Comparative evidence is limited, and most trials were too short to define uncommon or long-term harms.

2. Postpartum patient navigation improves several care processes

Type: Single-centre US randomised trial of 405 predominantly Black or Hispanic Medicaid-insured participants, published 2 October. A trained lay navigator addressed social barriers, coordinated appointments and supported transition to primary care for one year.

The prespecified composite of receiving all six essential care elements by 12 weeks was not improved (9.4% versus 7.9%). Nevertheless, navigation increased postpartum-visit completion (96% versus 80%), depression screening and linkage (86% versus 72%), and receipt of anticipatory guidance (65% versus 51%). At 11–13 months, primary-care attendance was 57% versus 30%.

Practice take-home: For UK services with high postnatal attrition or marked inequalities, this supports testing named navigators or link workers who can schedule care, address social barriers and ensure handover to primary care. Measure individual outcomes rather than relying on an all-or-none composite. Generalisability is uncertain: the intervention was resource-intensive, context-dependent and not powered for maternal morbidity or mortality.